Amyotrophic Lateral SclerosisEssay Preview: Amyotrophic Lateral SclerosisReport this essayOne day youĂ²Ăââ˘re a vibrant, healthy young individual. The next day, you find out you have a rare, currently untreatable, disease. You are diagnosed with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that causes degeneration throughout the brain and spinal cord. This disease is generally characterized by muscle weakness, but leaves mental and ocular sharpness intact, while the remainder of the body grows weaker and weaker. Currently, as above stated, there is no cure for this disease. However, hope may be just over the scientific horizon. Stem cell research and therapeutic cloning, with all of the ethical issues they entail, have the potential of producing a cure for this only partially understood disease.
Therapeutic cloning is a relatively recent development on the medical scene. Still not fully developed or researched, therapeutic cloning is only in the first stages of development. The process involves the extraction of unfertilized eggs from women during ovulation. Afterwards, the inner genetic material of the egg is removed and replaced with cumulus cells, small cells that are used by embryos for growth and development. Then, the egg is exposed to various chemicals designed to make it divide. From there, the egg divides many times into a blastocyst, a hollow ball filled with a clump of cells called the inner cell mass. This inner cell mass contains stem cells which can be induced into forming various cells which could later be injected into patients. By this process, replacement cells could be cultured in order to replace defective cells, thus providing a way to cure genetic disorders and diseases, such as ALS (Cibelli et al, 2001).
Once scientists are capable of cloning specific types of cells, such us nerve cells, cardiac cells, etc., cures for numerous forms of diseases could finally be available. In the case of ALS, scientists could grow the specifically needed motor-neuron cells and inject or implant them into the ALS patient, replacing the faulty cells with healthy, normally functioning cells. Other degenerative diseases, like AlzheimerĂ²Ăââ˘s, could also be treated. Someone blind from birth, in one or both eyes, could finally have sight. The possibilities of therapeutic cloning and cell replacement technology are limitless as to what miracles they could produce in the medical field. Unfortunately, due to ethical and legal issues, therapeutic cloning research is not completely
⢠a new form of science
Researching therapies for disabilities
The FDA in its 2006 letter to the U.S. Surgeon General described research on cloning that involves “to construct, replace, or re-create any cell at the molecular level, such as muscle or oocyte, bone-in and bone-out”.
Dr. Frank Hochberg, professor of biochemistry at the University of California, San Diego, said that the agency expected commercial advances in cloning to be “generous” as well as to show some promise for a regenerative medicine for “high-risk individuals”.
Dr. Mark Schmucker, chief scientist at the L.A. Foundation for Regenerative Medicine, said that the FDA had asked the company to produce an array of therapies for ALS, the type of “cancer” that was killing the brain.
The company declined a request for an initial public offering, saying that it planned to have “clinical studies and clinical testing” to do on its own. Dr. Hochberg also said the company planned to be able to do research into “biomedical and medical” applications for human stem cells.
However, in 2011 the FDA said it didn’t believe the company, based on the company’s “non-discretionary” testing, had the potential “high degree of assurance and regulatory certainty” needed to commercialize the therapies.
The FDA said that although the “high degree of certainty” is needed to license the products, it could also be expected from “federal laboratories and pharmaceutical research groups” if they are able to demonstrate certain safety or efficacy.
So if a patient is not receiving the therapy, what is the market for that medicine? Would that mean no cure for the disease, no potential treatments? The FDA says that the answer has to do with patient safety. This means that if a patient is being treated with a medication that may prevent their disease, they are taking that medication to prevent future diseases.
A patent application from the German biotechnology giant GmbH in late 2016 showed that the enzyme MMP9, also known as protease MMP, could prevent the degenerative degenerative disease ALS disease.
MMP9 is a common protein found in human blood, but most other proteins in blood do not contain MMP9, which may be part of the reason why several new diseases can now be treated with it compared to other proteins in blood.
Dr. Shulamith S. Khanna, an American professor of molecular genetics at the National Academy of Sciences, said the FDA asked GmbH if it would provide a patent for an antibiotic, and said that if the patents were filed as it required, “we would do more litigation.”
Dr. Yves Van Dijk of the University of Zurich, who is studying GmbH patent applications, added that it was “unbelievable as to the safety of this antibiotic if it works on human bodies and cells and only on human tissue, which would be like making the same type of drugs for
The FDA in its 2006 letter to the U.S. Surgeon General described research on cloning that involves “to construct, replace, or re-create any cell at the molecular level, such as muscle or oocyte, bone-in and bone-out”.
Dr. Frank Hochberg, professor of biochemistry at the University of California, San Diego, said that the agency expected commercial advances in cloning to be “generous” as well as to show some promise for a regenerative medicine for “high-risk individuals”.
Dr. Mark Schmucker, chief scientist at the L.A. Foundation for Regenerative Medicine, said that the FDA had asked the company to produce an array of therapies for ALS, the type of “cancer” that was killing the brain.
The company declined a request for an initial public offering, saying that it planned to have “clinical studies and clinical testing” to do on its own. Dr. Hochberg also said the company planned to be able to do research into “biomedical and medical” applications for human stem cells.
However, in 2011 the FDA said it didn’t believe the company, based on the company’s “non-discretionary” testing, had the potential “high degree of assurance and regulatory certainty” needed to commercialize the therapies.
The FDA said that although the “high degree of certainty” is needed to license the products, it could also be expected from “federal laboratories and pharmaceutical research groups” if they are able to demonstrate certain safety or efficacy.
So if a patient is not receiving the therapy, what is the market for that medicine? Would that mean no cure for the disease, no potential treatments? The FDA says that the answer has to do with patient safety. This means that if a patient is being treated with a medication that may prevent their disease, they are taking that medication to prevent future diseases.
A patent application from the German biotechnology giant GmbH in late 2016 showed that the enzyme MMP9, also known as protease MMP, could prevent the degenerative degenerative disease ALS disease.
MMP9 is a common protein found in human blood, but most other proteins in blood do not contain MMP9, which may be part of the reason why several new diseases can now be treated with it compared to other proteins in blood.
Dr. Shulamith S. Khanna, an American professor of molecular genetics at the National Academy of Sciences, said the FDA asked GmbH if it would provide a patent for an antibiotic, and said that if the patents were filed as it required, “we would do more litigation.”
Dr. Yves Van Dijk of the University of Zurich, who is studying GmbH patent applications, added that it was “unbelievable as to the safety of this antibiotic if it works on human bodies and cells and only on human tissue, which would be like making the same type of drugs for
The FDA in its 2006 letter to the U.S. Surgeon General described research on cloning that involves “to construct, replace, or re-create any cell at the molecular level, such as muscle or oocyte, bone-in and bone-out”.
Dr. Frank Hochberg, professor of biochemistry at the University of California, San Diego, said that the agency expected commercial advances in cloning to be “generous” as well as to show some promise for a regenerative medicine for “high-risk individuals”.
Dr. Mark Schmucker, chief scientist at the L.A. Foundation for Regenerative Medicine, said that the FDA had asked the company to produce an array of therapies for ALS, the type of “cancer” that was killing the brain.
The company declined a request for an initial public offering, saying that it planned to have “clinical studies and clinical testing” to do on its own. Dr. Hochberg also said the company planned to be able to do research into “biomedical and medical” applications for human stem cells.
However, in 2011 the FDA said it didn’t believe the company, based on the company’s “non-discretionary” testing, had the potential “high degree of assurance and regulatory certainty” needed to commercialize the therapies.
The FDA said that although the “high degree of certainty” is needed to license the products, it could also be expected from “federal laboratories and pharmaceutical research groups” if they are able to demonstrate certain safety or efficacy.
So if a patient is not receiving the therapy, what is the market for that medicine? Would that mean no cure for the disease, no potential treatments? The FDA says that the answer has to do with patient safety. This means that if a patient is being treated with a medication that may prevent their disease, they are taking that medication to prevent future diseases.
A patent application from the German biotechnology giant GmbH in late 2016 showed that the enzyme MMP9, also known as protease MMP, could prevent the degenerative degenerative disease ALS disease.
MMP9 is a common protein found in human blood, but most other proteins in blood do not contain MMP9, which may be part of the reason why several new diseases can now be treated with it compared to other proteins in blood.
Dr. Shulamith S. Khanna, an American professor of molecular genetics at the National Academy of Sciences, said the FDA asked GmbH if it would provide a patent for an antibiotic, and said that if the patents were filed as it required, “we would do more litigation.”
Dr. Yves Van Dijk of the University of Zurich, who is studying GmbH patent applications, added that it was “unbelievable as to the safety of this antibiotic if it works on human bodies and cells and only on human tissue, which would be like making the same type of drugs for
The FDA in its 2006 letter to the U.S. Surgeon General described research on cloning that involves “to construct, replace, or re-create any cell at the molecular level, such as muscle or oocyte, bone-in and bone-out”.
Dr. Frank Hochberg, professor of biochemistry at the University of California, San Diego, said that the agency expected commercial advances in cloning to be “generous” as well as to show some promise for a regenerative medicine for “high-risk individuals”.
Dr. Mark Schmucker, chief scientist at the L.A. Foundation for Regenerative Medicine, said that the FDA had asked the company to produce an array of therapies for ALS, the type of “cancer” that was killing the brain.
The company declined a request for an initial public offering, saying that it planned to have “clinical studies and clinical testing” to do on its own. Dr. Hochberg also said the company planned to be able to do research into “biomedical and medical” applications for human stem cells.
However, in 2011 the FDA said it didn’t believe the company, based on the company’s “non-discretionary” testing, had the potential “high degree of assurance and regulatory certainty” needed to commercialize the therapies.
The FDA said that although the “high degree of certainty” is needed to license the products, it could also be expected from “federal laboratories and pharmaceutical research groups” if they are able to demonstrate certain safety or efficacy.
So if a patient is not receiving the therapy, what is the market for that medicine? Would that mean no cure for the disease, no potential treatments? The FDA says that the answer has to do with patient safety. This means that if a patient is being treated with a medication that may prevent their disease, they are taking that medication to prevent future diseases.
A patent application from the German biotechnology giant GmbH in late 2016 showed that the enzyme MMP9, also known as protease MMP, could prevent the degenerative degenerative disease ALS disease.
MMP9 is a common protein found in human blood, but most other proteins in blood do not contain MMP9, which may be part of the reason why several new diseases can now be treated with it compared to other proteins in blood.
Dr. Shulamith S. Khanna, an American professor of molecular genetics at the National Academy of Sciences, said the FDA asked GmbH if it would provide a patent for an antibiotic, and said that if the patents were filed as it required, “we would do more litigation.”
Dr. Yves Van Dijk of the University of Zurich, who is studying GmbH patent applications, added that it was “unbelievable as to the safety of this antibiotic if it works on human bodies and cells and only on human tissue, which would be like making the same type of drugs for